Brivanib functions as a dual inhibitor of VEGF receptor tyrosine kinases,[48] which demonstrates potent antiproliferative and antiangiogenic effects on various tumor cells, including hepatoma cells.[49,50] Llovet et al[30] reported an ORR of 10% for brivanib based on modified response evaluation criteria in solid tumors compared to 2% for placebo. The gene discussed is NTRK1; the disease is hepatocellular carcinoma.